Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

Ioana Agache, Yang Song, Pablo Alonso-Coello, Yasmin Vogel, Claudio Rocha, Ivan Solà, Marilina Santero, Cezmi A Akdis, Mubeccel Akdis, Giorgio Walter Canonica, Tomas Chivato, Stefano Del Giacco, Thomas Eiwegger, Wytske Fokkens, Christos Georgalas, Philippe Gevaert, Claire Hopkins, Ludger Klimek, Valerie Lund, Robert NaclerioLiam O'Mahony, Susanna Palkonen, Oliver Pfaar, Jürgen Schwarze, Michael B Soyka, De Yun Wang, Luo Zhang, Carlos Canelo-Aybar, Oscar Palomares, Marek Jutel

Research output: Journal article (peer-reviewed)Journal article

86 Citations (Scopus)

Abstract

This systematic review evaluates the efficacy and safety of biologicals for chronic rhinosinusitis with nasal polyps (CRSwNP) compared with the standard of care. PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CRSwNP-related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. RCTs evaluated (dupilumab-2, omalizumab-4, mepolizumab-2, and reslizumab-1) included 1236 adults, with follow-up of 20-64 weeks. Dupilumab reduces the need for surgery (NFS) or oral corticosteroid (OCS) use (RR 0.28; 95% CI 0.20-0.39, moderate certainty) and improves with high certainty smell evaluated with UPSIT score (mean difference (MD) +10.54; 95% CI +9.24 to +11.84) and quality of life (QoL) evaluated with SNOT-22 (MD -19.14; 95% CI -22.80 to -15.47), with fewer treatment-related adverse events (TAEs) (RR 0.95; 95% CI 0.89-1.02, moderate certainty). Omalizumab reduces NFS (RR 0.85; 95% CI 0.78-0.92, high certainty), decreases OCS use (RR 0.38; 95% CI 0.10-1.38, moderate certainty), and improves high certainty smell (MD +3.84; 95% CI +3.64 to +4.04) and QoL (MD -15.65; 95% CI -16.16 to -15.13), with increased TAE (RR 1.73; 95% CI 0.60-5.03, moderate certainty). There is low certainty for mepolizumab reducing NFS (RR 0.78; 95% CI 0.64-0.94) and improving QoL (MD -13.3; 95% CI -23.93 to -2.67) and smell (MD +0.7; 95% CI -0.48 to +1.88), with increased TAEs (RR 1.64; 95% CI 0.41-6.50). The evidence for reslizumab is very uncertain.

Original languageEnglish
Pages (from-to)2337-2353
Number of pages17
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume76
Issue number8
DOIs
Publication statusPublished - Aug 2021
Externally publishedYes

Keywords

  • Adult
  • Biological Products/adverse effects
  • Humans
  • Nasal Polyps/drug therapy
  • Omalizumab/adverse effects
  • Quality of Life
  • Sinusitis/drug therapy

Fingerprint

Dive into the research topics of 'Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines'. Together they form a unique fingerprint.

Cite this